Is AXSM overvalued right now?
Based on our 2026 models, Axsome Therapeutics, Inc. (AXSM) appears overvalued at $242.60 with roughly 241.5% downside versus fair value. Confirm with valuation ratios and financials before acting.
Axsome Therapeutics, Inc. (AXSM) is currently Overvalued by 241.53%
Instant valuation answer
Axsome Therapeutics, Inc. (AXSM) appears overvalued by approximately 241.53% based on our live valuation percent and intrinsic value estimate derived from DCF, P/E Multiple, and P/S Multiple models. Valuation can still differ across analyst models, growth expectations, and risk assumptions.
- Downside (live) 241.53% (from live valuation API)
- Confidence (live) 8.5/10 (High conviction overvalued)
Confidence Score is based on the magnitude of upside or downside vs intrinsic value.
Fair value estimate
Unlock fair valueCurrent price
$242.60
Stock valuation checker
Search our company database (same as the site header). Choose a result or type a ticker and press Check valuation.
Explore Our Valuation Calculators
Why is Axsome Therapeutics, Inc. overvalued or undervalued?
Intrinsic value work anchors Axsome Therapeutics, Inc. on owner earnings and balance-sheet capacity; the current quote trades below that anchor, which frames the stock as relatively cheap on a fundamentals-first view.
Versus historical valuation bands, AXSM is closer to the lower end of where this business has traded when profitability and growth were comparable—useful context before reading any single headline multiple.
Forward market expectations are muted: the price does not require heroic assumptions to converge with our fair-value zone, but sector peers and macro rates still deserve a quick sanity check on the company page.
Key metrics
- P/E ratio
- 36.6x
- Revenue growth (TTM y/y)
- 5%
- Profit margin
- 21.8%
- Fair value (model)
- Unlock
Frequently asked questions — AXSM
What is Axsome Therapeutics, Inc.'s intrinsic value?
Our DCF, P/E Multiple, and P/S Multiple models estimate whether AXSM trades above or below fair value. At $242.60, Axsome Therapeutics, Inc. currently looks overvalued on this snapshot. Tickerplace Pro unlocks the full dollar fair value estimate.
How is Axsome Therapeutics, Inc.'s intrinsic value calculated?
Tickerplace calculates AXSM's fair value using Discounted Cash Flow (DCF), P/E Multiple, and P/S Multiple models. We compare the resulting intrinsic value estimate to the live market price to flag undervalued or overvalued positioning.
Is AXSM undervalued right now?
A stock is undervalued when price sits below a supportable fair value range. Check whether AXSM's gap aligns with fundamentals using the ratios and financial links on this page.
Related companies — valuation
Peers for AXSM: open their overvalued / undervalued view.